Z Squared Inc.

On May 14, 2026, the Board of Directors of the Company approved and adopted the Second Amended and Restated Bylaws of the Company (the "Second A&R Bylaws"), which became effective immediately. The Second A&R Bylaws amend and restate the Amended and Restated Bylaws of the Company as previously in effect (the "Prior Bylaws") solely to reflect the change in the Company's corporate name from "Coeptis Therapeutics Holdings, Inc." to "Z Squared Inc." effected in connection with the closing of the Merger. The Second A&R Bylaws did not amend, alter, or supplement any of the substantive provisions of the Prior Bylaws. A copy of the Second A&R Bylaws is filed as Exhibit 3.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference. The foregoing description of the Second A&R Bylaws is qualified in its entirety by reference to the full text of the Second A&R Bylaws.

During the three months ended March 31, 2026, no director or Section 16 officer of the Company adopted, modified, or terminated any 'Rule 10b5-1 trading arrangement' or any 'non-Rule 10b5-1 trading arrangement,' in each case as defined in Item 408 of Regulation S-K.